Fuller & Thaler Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-193,940	Closed	-$3.6M	–	558
2023 Q3	$3.6M	Sell	193,940 -7,520	-4%	-$85.1K	0.02%	306
2023 Q2	$2.23M	Buy	+201,460	New	+$2.81M	0.01%	349
2022 Q3	–	Sell	-165,310	Closed	-$2.28M	–	509
2022 Q2	$2.28M	Buy	165,310 +1,100	+0.7%	+$17.6K	0.02%	336
2022 Q1	$2.67M	Buy	164,210 +825	+0.5%	+$12.9K	0.02%	344
2021 Q4	$2.66M	Buy	+163,385	New	+$2.75M	0.02%	337
2015 Q1	–	Sell	-200	Closed	-$31K	–	723
2014 Q4	$31K	Sell	200 -800	-80%	-$148K	﹤0.01%	601
2014 Q3	$237K	Buy	+1,000	New	+$255K	0.01%	404

Fuller & Thaler Asset Management's ICPT Position: Q4 2023 in Review

Fuller & Thaler Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 193,940 shares — an estimated $3.6M sold.

Fuller & Thaler Asset Management first reported a position in ICPT in Q3 2014 and held it in 7 quarters. The position peaked at $3.6M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

Fuller & Thaler Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Fuller & Thaler Asset Management sold 193,940 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $3.6M.
Fuller & Thaler Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 7 quarters.
Fuller & Thaler Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $3.6M in Q3 2023.
0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.